Mechanisms of Severe Acute Influenza Consortium (MOSAIC) (MOSAIC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00965354|
Recruitment Status : Completed
First Posted : August 25, 2009
Last Update Posted : June 8, 2015
Influenza A is one of the best studied viruses, but continues to have a very large impact on human and animal health. In addition to causing outbreaks of winter flu, it sometimes mutates to create a new virus that spreads quickly around the world. It is puzzling that the same virus appears to cause minor or absent symptoms in some people while killing others. Much remains to be understood.
We have assembled an unprecedented group of internationally renowned scientists from England and Scotland who will together focus on studying a few hundred people hospitalised during the current swine flu pandemic. Such a largescale project has never before been attempted, but we are now poised to work together and integrate the many recent advances in biomedical science that relate to understanding how influenza causes disease.
The ultimate goal of this collaborative, intensive study is to discover new and effective treatments and to develop better vaccines that can be used in future outbreaks. By integrating the information that we will gather, we will create a unique overview of how influenza causes illness and what might be done to improve patient management.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||257 participants|
|Official Title:||Mechanisms of Severe Acute Influenza Consortium (MOSAIC)|
|Study Start Date :||December 2009|
|Actual Primary Completion Date :||February 2011|
|Actual Study Completion Date :||February 2011|
Patients admitted to hospital with a suspected or confirmed influenza diagnosis on admission
- Detailed clinical phenotype. Clinicopathological correlation will then be sought between the clinical phenotype and pathological parameters measured as per work packages. [ Time Frame: 3 years ]
- Response to drug treatment and the effect of drug resistance if that emerges. [ Time Frame: 3 years ]
Biospecimen Retention: Samples With DNA
A) Swabs and secretions from the nose and throat B) Blood C) Sputum D) Urine E) Stool
In addition, if the patients are having further respiratory sample collection as part of their routine care, for example tracheal aspirates, bronchial lavage and other samples then we would like to take an additional amount of these samples for our research.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00965354
|Alder Hey Children's Foundation NHS Trust|
|Liverpool, United Kingdom, L12 2AP|
|Royal Liverpool University Hospital|
|Liverpool, United Kingdom, L7 8XP|
|Liverpool Women's NHS Foundation Trust|
|Liverpool, United Kingdom, L8 7SS|
|Aintree Hospitals NHS Trust|
|Liverpool, United Kingdom, L9 7AL|
|Chelsea and Westminster Hospital NHS Foundation Trust|
|London, United Kingdom, SW10 9NH|
|Royal Brompton and Harefield NHS Foundation Trust|
|London, United Kingdom, SW3 6NP|
|Imperial College Healthcare NHS Trust|
|London, United Kingdom, W2 1PG|
|Wirral University Teaching Hospital NHS Foundation Trust|
|Wirral, United Kingdom, CH49 5PE|
|Principal Investigator:||Peter JM Openshaw||Imperial College London|